BioMarin Pharmaceutical Inc.
BMRN today announced the pricing of an underwritten public offering
of 6,500,000 shares of its common stock. The gross proceeds to BioMarin from
this offering are expected to be approximately $248,885,000, before deducting
underwriting discounts and commissions and other estimated offering expenses
payable by BioMarin. The offering is expected to close on or about June 5,
2012, subject to customary closing conditions. BioMarin has also granted to
the underwriters a 30-day option to purchase from it up to an additional
650,000 shares of its common stock. BioMarin intends to use the net proceeds
from this offering primarily for general corporate purposes, including working
capital and research and development.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in